Top Scoops

Book Reviews | Gordon Campbell | Scoop News | Wellington Scoop | Community Scoop | Search

 

WHO TB Strategy Out Of Reach For Many Countries

WHO TB Strategy Out Of Reach For Many Endemic Countries


by Dr Bobby John and Tim France, PhD

A much larger TB drug resistance problem exists than researchers previously thought. New global data on TB, published this week by the World Health Organization (WHO), highlight serious weaknesses in many national TB programmes, increasing the potential for widespread TB drug resistance. How did we reach this precarious state?

Ask a WHO expert that question and they assert that increasing levels of TB drug resistance: "reflects a failure to implement the WHO Stop TB Strategy." The strategy hopefully maps out the steps that national TB control programmes need to take. By all accounts then, our national TB programmes are failing us.

The bacterium that causes tuberculosis (TB), Mycobacterium tuberculosis, is naturally sensitive to the antibiotic drugs used to treat the disease. The accepted truth about how TB drug resistance starts is that it is mostly 'acquired' in individual patients, because of inadequate treatment with TB drugs, now at least 40 years old.

Poor patient drug adherence, or the use of too few drugs leads – the story goes – to various forms of drug resistant TB. Multidrug-resistant TB (MDR-TB) is a specific type that does not respond to the two most powerful anti-TB drugs. Latest estimates are that MDR-TB makes up about 4% of all new and previously-treated TB globally. Apparently, our antiquated TB drugs are failing us too.

Drug resistant TB is already geographically widespread, including in places where TB control programmes have been in place for many years. But incredibly little is known about just how much TB drug resistance there is outside of capital cities, for example, and even in some entire countries where drug resistance may be common because of historically poor TB control.

No progress can be made if the TB clinics are there but the patients are not. Today's standard test for TB relies on a technique (sputum microscopy) invented over a hundred years ago. It provides no information about drug resistance. Apparently TB diagnosis is also failing us.

Too many weak points to deal with? A further litany of vital TB programme components has also been ignored for years, in favour of a single jewel in the TB strategy's crown: directly-observed treatment short course, or DOTS. In many places, a consistent lack of focus and investment has led to:

- Chronically weak TB diagnostic and laboratory services;
- Infrequent and incomplete TB drug resistance surveillance;
- Inadequate management of individual drug resistant TB cases;
- Paltry TB infection control measures, including in health care settings.

Predictably, many TB-endemic countries have indeed failed to meet the exacting standards of the WHO Stop TB Strategy. Given the circumstances in many countries where TB is rife, what is surprising is that they should be asked to pursue such a pipedream.

DOTS was supposed to stem TB drug resistance. Because of sloppy and unimaginative implementation, it is evidently failing us. As the full extent of TB drug resistance comes to light, prioritising TB drug delivery above all other areas of TB diagnosis and care looks increasingly like WHO has been building a house, just without foundations.

We cannot now claim to be surprised when a decade of overlooking the systemic challenges faced by high TB countries brings the entire house tumbling down.

Promoting policy frameworks is no replacement for working together to achieve what needs to be done to address TB. The Global Plan to Stop TB, (2006-2015), launched by the Stop TB Partnership just over a year ago, is a road map for such a coordinated action.

WHO urgently needs to look beyond 'their' Stop TB Strategy to help promote and coordinate the comprehensive range of actions set out in the Plan – and to recognise the track record of over five hundred global partners who put their name behind it.

When she took office just a few months ago, the new WHO Director-General, Dr Margaret Chan, identified the organisation's many partnerships as one of her immediate priorities. "Either the partnerships have to change or we have to change or both of us have to change to be more relevant," she said. "What is important to me is, are we getting the results that matter?"

In the case of controlling TB drug resistance, the answer is an unequivocal no.

*************

ABOUT AUTHORS:

Dr Bobby John, is the Executive Director of the Center for Sustainable Health & Development, India, and President of Global Health Advocates ( www.ghadvocates.org)
and
Dr Tim France, is Technical and Policy Adviser to Health & Development Networks ( www.hdnet.org ), and Chairman of the Stop TB Partnership ( www.stoptb.org) Media and Events Task Force.


© Scoop Media

 
 
 
Top Scoops Headlines

 

Binoy Kampmark: Predictable Monstrosities: Priti Patel Approves Assange’s Extradition
The only shock about the UK Home Secretary’s decision regarding Julian Assange was that it did not come sooner. In April, Chief Magistrate Senior District Judge Paul Goldspring expressed the view that he was “duty-bound” to send the case to Priti Patel to decide on whether to extradite the WikiLeaks founder to the United States to face 18 charges, 17 grafted from the US Espionage Act of 1917... More>>

Digitl: Are we happy living in Handy's Age of Unreason?
In 1989 Charles Handy wrote The Age of Unreason. It's a book that looked forward to a time where telecommuting would be an everyday reality. We live in that world today, although we use the term working from home. The book contains other predictions that were on the money... More>>


Reactionary Succession: Peter Dutton, Australia’s New Opposition Leader
The devastation wrought on Australia’s Coalition government on May 21 by the electorate had a stunning, cleansing effect. Previously inconceivable scenarios were played out in safe, Liberal-held seats that had, for decades, seen few, if any challenges, from an alternative political force. But the survival of one figure would have proved troubling, not only to the new Labor government, but to many Liberal colleagues lamenting the ruins. The pugilists and head knockers, however, would have felt some relief. Amidst the bloodletting, hope... More>>


Digitl: Infrastructure Commission wants digital strategy
Earlier this month Te Waihanga, New Zealand’s infrastructure commission, tabled its first Infrastructure Strategy: Rautaki Hanganga o Aotearoa. Te Waihanga describes its document as a road map for a thriving New Zealand... More>>


Binoy Kampmark: Leaking For Roe V Wade
The US Supreme Court Chief Justice was furious. For the first time in history, the raw judicial process of one of the most powerful, and opaque arms of government, had been exposed via media – at least in preliminary form. It resembled, in no negligible way, the publication by WikiLeaks of various drafts of the Trans-Pacific Partnership... More>>




The Conversation: Cheaper food comes with other costs – why cutting GST isn't the answer

As New Zealand considers the removal of the goods and services tax (GST) from food to reduce costs for low income households, advocates need to consider the impact cheap food has on the environment and whether there are better options to help struggling families... More>>